These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15829291)

  • 1. Structure-based design and characterization of a Novel IL-6 antagonist peptide.
    Yang Z; Feng J; Li Y; Hu M; Song L; Yu M; Qin W; Shen B
    Mol Immunol; 2005 May; 42(9):1015-21. PubMed ID: 15829291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel hIL-6 antagonist peptide from computer-aided design contributes to suppression of apoptosis in M1 cells.
    Yang Z; Feng J; Hu M; Li Y; Yu M; Qin W; Shen B
    Biochem Biophys Res Commun; 2004 Dec; 325(2):518-24. PubMed ID: 15530423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rational designed antagonist derived from the complex structure of interleukin-6 and its receptor affectively blocking interleukin-6 might be a promising treatment in multiple myeloma.
    Feng J; Yang Z; Li Y; Hu M; Yu M; Qin W; Sun J; Shen B
    Biochimie; 2006 Sep; 88(9):1265-73. PubMed ID: 16626851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The design of antagonist peptide of hIL-6 based on the binding epitope of hIL-6 by computer-aided molecular modeling.
    Feng J; Li Y; Shen B
    Peptides; 2004 Jul; 25(7):1123-31. PubMed ID: 15245871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design of an agonistic peptide targeting Fas.
    Yoshimori A; Takasawa R; Hayakawa A; Mizuno M; Yoshida J; Tanuma S
    Apoptosis; 2005 Mar; 10(2):323-9. PubMed ID: 15843893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational design of potent mimic peptide derived from monoclonal antibody: antibody mimic design.
    Feng J; Li Y; Zhang W; Shen B
    Immunol Lett; 2005 May; 98(2):311-6. PubMed ID: 15860233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of some viral IL-6 electrostatic properties compared to IL-6 contributes to a loss of alpha receptor component recruitment.
    Perret D; Rousseau F; Tran V; Gascan H
    Proteins; 2005 Jul; 60(1):14-26. PubMed ID: 15861391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel domain antibody rationally designed against TNF-alpha using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides.
    Qin W; Feng J; Li Y; Lin Z; Shen B
    Mol Immunol; 2007 Mar; 44(9):2355-61. PubMed ID: 17125837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De-novo design of complementary (antisense) peptide mini-receptor inhibitor of interleukin 18 (IL-18).
    Bhakoo A; Raynes JG; Heal JR; Keller M; Miller AD
    Mol Immunol; 2004 Nov; 41(12):1217-24. PubMed ID: 15482857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo design of ErbB2 epitope targeting fusion protein stabilized by coiled coil structure.
    Wang J; Feng J; Shi M; Qian L; Chen L; Yu M; Xu R; Shen B; Guo N
    Mol Immunol; 2008 Jan; 45(1):106-16. PubMed ID: 17572496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor.
    Takasaki W; Kajino Y; Kajino K; Murali R; Greene MI
    Nat Biotechnol; 1997 Nov; 15(12):1266-70. PubMed ID: 9359109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions.
    Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH
    J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based virtual screening and characterization of a novel IL-6 antagonistic compound from synthetic compound database.
    Wang J; Qiao C; Xiao H; Lin Z; Li Y; Zhang J; Shen B; Fu T; Feng J
    Drug Des Devel Ther; 2016; 10():4091-4100. PubMed ID: 28008232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo design TNF-alpha antagonistic peptide based on the complex structure of TNF-alpha with its neutralizing monoclonal antibody Z12.
    Qin W; Feng J; Li Y; Lin Z; Shen B
    J Biotechnol; 2006 Aug; 125(1):57-63. PubMed ID: 16522339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A journey in structure-based drug discovery: from designed peptides to protein surface topomimetics as antibiotic and antiangiogenic agents.
    Dings RP; Mayo KH
    Acc Chem Res; 2007 Oct; 40(10):1057-65. PubMed ID: 17661438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformational perturbation of interleukin-2: a strategy for the design of cytokine analogs.
    Landgraf BE; Williams DP; Murphy JR; Smith KA; Ciardelli TL
    Proteins; 1991; 9(3):207-16. PubMed ID: 2006138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an IL-6 antagonist peptide that induces apoptosis in 7TD1 cells.
    Manfredini R; Tenedini E; Siena M; Tagliafico E; Montanari M; Grande A; Zanocco-Marani T; Poligani C; Zini R; Gemelli C; Bergamaschi A; Vignudelli T; De Rienzo F; De Benedetti PG; Menziani MC; Ferrari S
    Peptides; 2003 Aug; 24(8):1207-20. PubMed ID: 14612193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel BLyS antagonist peptide designed based on the 3-D complex structure of BCMA and BLyS.
    Sun J; Feng J; Li Y; Shen B
    Biochem Biophys Res Commun; 2006 Aug; 346(4):1158-62. PubMed ID: 16793005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinases.
    Hausherr A; Tavares R; Schäffer M; Obermeier A; Miksch C; Mitina O; Ellwart J; Hallek M; Krause G
    Oncogene; 2007 Jul; 26(34):4987-98. PubMed ID: 17310994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.